BioSpherix, Ltd.

01/20/2023

Join us at ASME's free webinar to discuss exciting advancements in biomedical innovation! Register now: https://asme.zoom.us/webinar/register/WN_JNE5jmzNTa-T__C_frLgmw

12/21/2022

Have your cell cultures been naughty this year, or nice?
Happy Holidays, from the BioSpherix family.

12/01/2022

Enhanced Self-Renewal of HSC Under Physioxia:
Physioxia induces downregulation of Tet2 in Hematopoietic Stem Cells, report Aljoufi et al.

Read more (open access): https://ashpublications.org/blood/article/doi/10.1182/blood.2022015499/485747/Physioxia-induced-Downregulation-of-Tet2-in

11/30/2022

Goal: discuss and identify measurement needs for characterizing biofabricated, tissue en

11/29/2022

Physioxia Influences Gene Methylation:
Dogan et al. use physiological oxygen to examine epigenetic modification in pluripotent stem cells.

Read more (open access): https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9148100/

11/28/2022

The goal of the alliance is to allow cell-based therapies to be manufactured cost-effectively with superior efficacy and safety.

11/21/2022

Osteogenesis and HIF Signaling in the Clinic: An in-depth review of recent progress in HIF-regulated bone regeneration provides evidence for novel tissue repair strategies.

Read more: https://pubmed.ncbi.nlm.nih.gov/35913258/

Bone tissue destruction leads to severe pain, physical flaws, and loss of motility. Bone repair using biocompatible and osteo-inductive scaffolds is regarded as a viable and potential therapeutic approach. However, for large-scale bone regeneration, oxygen and nutrient supply have become limiting fa...

11/17/2022

Altering O2 in Solid Tumor Studies:
Herrera-Campos et al. review the role of hyperoxia and the immune system in novel treatments for solid tumors.

Read more (open access): https://www.mdpi.com/2072-6694/14/11/2740/htm

Hyperoxia is used in order to counteract hypoxia effects in the TME (tumor microenvironment), which are described to boost the malignant tumor phenotype and poor prognosis. The reduction of tumor hypoxic state through the formation of a non-aberrant vasculature or an increase in the toxicity of the....

11/16/2022

Identifying EV Uptake Signals in Pancreatic Cancer: Nigri et al. mimic pathophysiologic conditions to identify a potential target for therapeutic intervention into aggressive pancreatic ductal carcinoma.

Read more (open access): https://pubmed.ncbi.nlm.nih.gov/35917363/

In pancreatic ductal adenocarcinoma (PDAC), signaling from stromal cells is implicated in metastatic progression. Tumor-stroma cross-talk is often mediated through extracellular vesicles (EVs). We previously reported that EVs derived from cancer-associated stromal fibroblasts (CAFs) that are abundan...

11/14/2022

Intestinal Wound Healing and HIF: Steiner et al. review the double-edged sword HIF present over the course of the metabolic response to chronic intestinal inflammation.

Read more: https://pubmed.ncbi.nlm.nih.gov/35912990/

The healthy mammalian intestine is lined by a single layer of epithelial cells. These cells provide a selectively permeable barrier to luminal contents and normally do so in an efficient and effective manner. Barrier function in the healthy mucosa is provided via several mechanisms including epithel...

11/10/2022

Relevant miRNA patterns under pathophysioxia:
Majewska et al. study the role of PTEN in kidney cancer by mimicking the TME in vitro.

Read more (open access): https://pubmed.ncbi.nlm.nih.gov/35625614/

MicroRNAs are post-transcriptional regulators of gene expression, and disturbances of their expression are the basis of many pathological states, including cancers. The miRNA pattern in the context of tumor microenvironment explains mechanisms related to cancer progression and provides a potential t...

11/09/2022

Neuroinflammation Regulation Therapies Tested Using Hypoxia: Wang et al. recreate pathophysiological conditions to study neuroprotection after cardiac arrest-induced brain injury.

Read more: https://pubmed.ncbi.nlm.nih.gov/35921049/

Cardiac arrest (CA) is common and devastating, and neuroprotective therapies for brain injury after CA remain limited. Neuroinflammation has been a target for two promising but underdeveloped post-CA therapies: neural stem cell (NSC) engrafting and glibenclamide (GBC). It is critical to understand w...